Boston Scientific Initiates Trial to Evaluate WATCHMAN FLX(TM) Left Atrial Appendage Closure Device as First-Line Treatment for People at Risk of Stroke

Trial to study next-generation device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation MARLBOROUGH, Mass., Oct. 29, 2020 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporatio... Devices, Interventional, Cardiology Boston Scientific, WATCHMAN FLX, Left Atrial Appendage, atrial fibrillation
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news